161 related articles for article (PubMed ID: 27129215)
1. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
2. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
4. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
[TBL] [Abstract][Full Text] [Related]
5. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based Modeling for the Prediction of Pharmacophore Features for Multi-targeted Inhibition of the Arachidonic Acid Cascade.
Saroj Devi N; Shanmugam R; Ghorai J; Ramanan M; Anbarasan P; Doble M
Mol Inform; 2018 Mar; 37(3):. PubMed ID: 28991413
[TBL] [Abstract][Full Text] [Related]
7. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
Ferguson AD; McKeever BM; Xu S; Wisniewski D; Miller DK; Yamin TT; Spencer RH; Chu L; Ujjainwalla F; Cunningham BR; Evans JF; Becker JW
Science; 2007 Jul; 317(5837):510-2. PubMed ID: 17600184
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Levent S; Gerstmeier J; Olgaç A; Nikels F; Garscha U; Carotti A; Macchiarulo A; Werz O; Banoglu E; Çalışkan B
Eur J Med Chem; 2016 Oct; 122():510-519. PubMed ID: 27423639
[TBL] [Abstract][Full Text] [Related]
11. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
[TBL] [Abstract][Full Text] [Related]
12. 5-Lipoxygenase-activating protein rescues activity of 5-lipoxygenase mutations that delay nuclear membrane association and disrupt product formation.
Gerstmeier J; Newcomer ME; Dennhardt S; Romp E; Fischer J; Werz O; Garscha U
FASEB J; 2016 May; 30(5):1892-900. PubMed ID: 26842853
[TBL] [Abstract][Full Text] [Related]
13. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U
Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP.
Häfner AK; Gerstmeier J; Hörnig M; George S; Ball AK; Schröder M; Garscha U; Werz O; Steinhilber D
Biochim Biophys Acta; 2015 Nov; 1851(11):1465-72. PubMed ID: 26327594
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.
Garscha U; Romp E; Pace S; Rossi A; Temml V; Schuster D; König S; Gerstmeier J; Liening S; Werner M; Atze H; Wittmann S; Weinigel C; Rummler S; Scriba GK; Sautebin L; Werz O
Sci Rep; 2017 Aug; 7(1):9398. PubMed ID: 28839250
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.
Temml V; Garscha U; Romp E; Schubert G; Gerstmeier J; Kutil Z; Matuszczak B; Waltenberger B; Stuppner H; Werz O; Schuster D
Sci Rep; 2017 Feb; 7():42751. PubMed ID: 28218273
[TBL] [Abstract][Full Text] [Related]
17. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho JD; Lee MR; Rauch CT; Aznavour K; Park JS; Luz JG; Antonysamy S; Condon B; Maletic M; Zhang A; Hickey MJ; Hughes NE; Chandrasekhar S; Sloan AV; Gooding K; Harvey A; Yu XP; Kahl SD; Norman BH
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129800. PubMed ID: 33246032
[TBL] [Abstract][Full Text] [Related]
18. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
Fang WF; Douglas IS; Wang CC; Kao HC; Chang YT; Tseng CC; Huang KT; Chang HC; Lin MC
PLoS One; 2014; 9(7):e102622. PubMed ID: 25025775
[TBL] [Abstract][Full Text] [Related]
19. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
20. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
